Recommended Pages at www-origin2.roche.com
Roche - Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C
www-origin2.roche.com — “Roche - Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C” View full resource at www-origin2.roche.com
Most Recently Shared on May 17, 2011 at 4:20 pm By:
eyeonfda Pharma and Health Lawyer
Roche and Merck Establish Strategic Agreements re Against Chronic Hep C http://ow.ly/4WBvh
Roche - Xeloda in combination with oxaliplatin approved in Europe for the adjuvant treatment of patients with early colon cancer
www-origin2.roche.com — “Roche - Xeloda in combination with oxaliplatin approved in Europe for the adjuvant treatment of patients with early colon cancer” View full resource at www-origin2.roche.com
Most Recently Shared on March 30, 2010 at 6:54 am By:
eyeonfda Pharma and Health Lawyer
Xeloda in combo w/oxaliplatin approved in EU 4 adjuvant treatment of patients with early colon cancer - http://ow.ly/1sutD
Roche - Roche provides update on phase III study of Avastin in men with late stage prostate cancer
www-origin2.roche.com — “Roche - Roche provides update on phase III study of Avastin in men with late stage prostate cancer” View full resource at www-origin2.roche.com
Most Recently Shared on March 12, 2010 at 2:52 pm By:
eyeonfda Pharma and Health Lawyer
Roche provides update on phase III study of Avastin in men with late stage prostate cancer - http://ow.ly/1i6B1
Roche - Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold
www-origin2.roche.com — “Roche - Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold” View full resource at www-origin2.roche.com
Most Recently Shared on March 8, 2010 at 2:44 pm By:
eyeonfda Pharma and Health Lawyer
Roche and Biogen Idec suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) based on DSMB http://ow.ly/1fyZz
Roche - US FDA approves Rituxan/MabThera for the most common type of adult leukemia
www-origin2.roche.com — “Roche - US FDA approves Rituxan/MabThera for the most common type of adult leukemia” View full resource at www-origin2.roche.com
Most Recently Shared on February 19, 2010 at 12:33 pm By:
eyeonfda Pharma and Health Lawyer
FDA approves Rituxan/MabThera for the most common type of adult leukemia - http://ow.ly/191eI
Roche - Roche study drug may offer valuable new treatment option for patients with type 2 diabetes
www-origin2.roche.com — “Roche - Roche study drug may offer valuable new treatment option for patients with type 2 diabetes” View full resource at www-origin2.roche.com
Most Recently Shared on February 11, 2010 at 1:05 pm By:
eyeonfda Pharma and Health Lawyer
Phase III study results on Roche diabetes candidate - http://ow.ly/16gvL
Roche - Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer
www-origin2.roche.com — “Roche - Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer” View full resource at www-origin2.roche.com
Most Recently Shared on September 24, 2009 at 12:47 pm By:
eyeonfda Pharma and Health Lawyer
Roche - Herceptin demonstrates survival benefit for patients with high levels of HER2 in their stomach cancer http://bit.ly/GONkd
Roche - MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemia
www-origin2.roche.com — “Roche - MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemia” View full resource at www-origin2.roche.com
Most Recently Shared on September 3, 2009 at 1:43 pm By:
eyeonfda Pharma and Health Lawyer
MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemia - http://bit.ly/Cv4uN
Roche - European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer
www-origin2.roche.com — “Roche - European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer” View full resource at www-origin2.roche.com
Most Recently Shared on July 29, 2009 at 8:31 pm By:
eyeonfda Pharma and Health Lawyer
Euro approval broader label for Avastin allowing combo w/docetaxel as 1st-line trtmnt of adv (metastatic) breast cancer http://bit.ly/oQIBu
Roche - MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns
www-origin2.roche.com — “Roche - MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns” View full resource at www-origin2.roche.com
Most Recently Shared on July 24, 2009 at 2:27 pm By:
eyeonfda Pharma and Health Lawyer
Roche - MabThera receives positive Euro opinion when chronic lymphocytic leukaemia returns http://bit.ly/9l3qH http://bit.ly/9l3qH
Roche - Xeloda in combination with oxaliplatin shown to be effective in early colon cancer
www-origin2.roche.com — “Roche - Xeloda in combination with oxaliplatin shown to be effective in early colon cancer” View full resource at www-origin2.roche.com
Most Recently Shared on July 20, 2009 at 2:10 pm By:
eyeonfda Pharma and Health Lawyer
Xeloda in combination with oxaliplatin shown to be effective in early colon cancer http://bit.ly/14KIs0
Roche - New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancer
www-origin2.roche.com — “Roche - New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancer” View full resource at www-origin2.roche.com
Most Recently Shared on July 13, 2009 at 1:28 pm By:
eyeonfda Pharma and Health Lawyer
New data phase III SATURN study of Tarceva in patients with advanced lung cancer http://bit.ly/1Z8lQi
Roche - New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis
www-origin2.roche.com — “Roche - New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis” View full resource at www-origin2.roche.com
Most Recently Shared on June 11, 2009 at 1:43 pm By:
eyeonfda Pharma and Health Lawyer
New data show ability of MabThera 2 reduce progression of jt damage when used as 1st-line biologic in RA - http://bit.ly/KtFmV
Roche - Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis
www-origin2.roche.com — “Roche - Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis” View full resource at www-origin2.roche.com
Most Recently Shared on May 26, 2009 at 2:44 pm By:
eyeonfda Pharma and Health Lawyer
2-yr data reinforce effectiveness of ACTEMRA in inhibiting joint damage / improving physical function in patients RA http://twurl.nl/mwxzsh
Roche - Roche responds to WHO move to influenza pandemic alert phase 5
www-origin2.roche.com — “Roche - Roche responds to WHO move to influenza pandemic alert phase 5” View full resource at www-origin2.roche.com
Most Recently Shared on April 30, 2009 at 11:04 am By:
eyeonfda Pharma and Health Lawyer
Roche responds to WHO move to influenza pandemic alert phase 5 - http://bit.ly/HUMF6
